US Patent

US8871745 — Proteasome inhibitors

Method of Use · Assigned to Millennium Pharmaceuticals Inc · Expires 2027-08-06 · 1y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel compounds and pharmaceutical compositions that inhibit proteasomes, useful in treating various diseases.

USPTO Abstract

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Drugs covered by this patent

ixazomib-citrate (IXAZOMIB CITRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2434`	—	ixazomib-citrate
`U-2434`	—	ixazomib-citrate
`U-2434`	—	ixazomib-citrate

Patent Metadata

Patent number: US8871745
Jurisdiction: US
Classification: Method of Use
Expires: 2027-08-06
Drug substance claim: No
Drug product claim: No
Assignee: Millennium Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.